Lin Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lin Luo has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Shizhong Bu
Diabetes Research Center, School of Medicine, Ningbo University, Ningbo, Zhejiang 315211, P.R. China
3 shared publications Danping Wang
Zhejiang Provincial Key Laboratory of Pathophysiology, Medical School of Ningbo University Zhejiang China
2 shared publications- Junming Guo
Department of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo, China
2 shared publications - Yabin Zhu
Health Science Center, Ningbo University, Ningbo, China
2 shared publications - Yanyan Yuan
Runliang Diabetes Laboratory, Diabetes Research Center, School of Medicine, Ningbo University, 818 Fenghua Road, Ningbo City, 315211, Zhejiang, People's Republic of China
2 shared publications - Beiyan Bao
Department of Nephrology , Ningbo Yinzhou No. 2 Hospital , Ningbo , Zhejiang , P.R China
1 shared publication
Latest Publications
- Open Access
- 1 January 2018
- Published by Medknow in Neural Regeneration Research
- Vol. 13 (6) , 1087-1095
Efficacy of epalrestat plus α-lipoic acid combination therapy versus monotherapy in patients with diabetic peripheral neuropathy: a meta-analysis of 20 randomized controlled trials
Objective: To evaluate the efficacy of α-lipoic acid (ALA) plus epalrestat combination therapy in the treatment of diabetic peripheral neuropathy (DPN). Data Sources: The electronic databases of PubMed, Medline, Embase, the Cochrane Library, the Chinese National Knowledge Infrastructure, the Wanfang Database and the Chinese Biomedical Database were used to retrieve relevant studies without language restrictions. The search was conducted from the inception of each database to 7 October 2016. The key terms were (diabetic peripheral neuropathy or diabetic neuropathy or DPN) AND (α-lipoic acid or lipoic acid or thioctic acid) AND epalrestat. Data Selection: All of the eligible studies met the following inclusion criteria: (1) Randomized controlled trials that compared efficacy and safety of epalrestat plus ALA combination therapy versus epalrestat or ALA monotherapy in patients with DPN. (2) The minimum duration of treatment was 2 weeks. (3) The DPN patients were diagnosed using the World Health Organization standardized type 2 diabetes mellitus and DPN criteria. (4) Studies contained at least one measure that could reflect the efficacy of the drug and nerve conduction velocities. Studies in which the control group used epalrestat or ALA combined with other drugs were excluded. Statistical analyses were performed using STATA software for meta-analysis. Outcome Measures: The primary outcomes were the therapeutic efficacy, median motor nerve conduction velocity (MNCV), median sensory nerve conduction velocity (SNCV), peroneal MNCV and peroneal SNCV. Results: Twenty studies with 1894 DPN patients were included, including 864 patients in the ALA plus epalrestat group, 473 in the ALA group and 557 in the epalrestat group. The efficacy of ALA plus epalrestat combination therapy was superior to ALA and epalrestat monotherapies (RR = 1.29, 95% CI: 1.21–1.38; RR = 1.43, 95% CI: 1.34–1.54, respectively). ALA plus epalrestat combination therapy also significantly improved median MNCV (WMD = 5.41, 95% CI: 2.07–8.75), median SNCV (WMD = 5.87, 95% CI: 1.52–10.22), peroneal MNCV (WMD = 5.59, 95% CI: 2.70–8.47) and peroneal SNCV (WMD = 4.57, 95% CI: 2.46–6.68). Conclusion: ALA plus epalrestat combination therapy was superior to ALA and epalrestat monotherapies for clinical efficacy and nerve conduction velocities in patients with DPN.
- 1 January 2018
- Published by Medknow in Neural Regeneration Research
- Vol. 13 (6) , 1087-1095
Open AccessEfficacy of epalrestat plus α-lipoic acid combination therapy versus monotherapy in patients with diabetic peripheral neuropathy: a meta-analysis of 20 randomized controlled trials
Objective: To evaluate the efficacy of α-lipoic acid (ALA) plus epalrestat combination therapy in the treatment of diabetic peripheral neuropathy (DPN). Data Sources: The electronic databases of PubMed, Medline, Embase, the Cochrane Library, the Chinese National Knowledge Infrastructure, the Wanfang Database and the Chinese Biomedical Database were used to retrieve relevant studies without language restrictions. The search was conducted from the inception of each database to 7 October 2016. The key terms were (diabetic peripheral neuropathy or diabetic neuropathy or DPN) AND (α-lipoic acid or lipoic acid or thioctic acid) AND epalrestat. Data Selection: All of the eligible studies met the following inclusion criteria: (1) Randomized controlled trials that compared efficacy and safety of epalrestat plus ALA combination therapy versus epalrestat or ALA monotherapy in patients with DPN. (2) The minimum duration of treatment was 2 weeks. (3) The DPN patients were diagnosed using the World Health Organization standardized type 2 diabetes mellitus and DPN criteria. (4) Studies contained at least one measure that could reflect the efficacy of the drug and nerve conduction velocities. Studies in which the control group used epalrestat or ALA combined with other drugs were excluded. Statistical analyses were performed using STATA software for meta-analysis. Outcome Measures: The primary outcomes were the therapeutic efficacy, median motor nerve conduction velocity (MNCV), median sensory nerve conduction velocity (SNCV), peroneal MNCV and peroneal SNCV. Results: Twenty studies with 1894 DPN patients were included, including 864 patients in the ALA plus epalrestat group, 473 in the ALA group and 557 in the epalrestat group. The efficacy of ALA plus epalrestat combination therapy was superior to ALA and epalrestat monotherapies (RR = 1.29, 95% CI: 1.21–1.38; RR = 1.43, 95% CI: 1.34–1.54, respectively). ALA plus epalrestat combination therapy also significantly improved median MNCV (WMD = 5.41, 95% CI: 2.07–8.75), median SNCV (WMD = 5.87, 95% CI: 1.52–10.22), peroneal MNCV (WMD = 5.59, 95% CI: 2.70–8.47) and peroneal SNCV (WMD = 4.57, 95% CI: 2.46–6.68). Conclusion: ALA plus epalrestat combination therapy was superior to ALA and epalrestat monotherapies for clinical efficacy and nerve conduction velocities in patients with DPN.
- Open Access
- 8 September 2017
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 17 (1) , 1-9
Radix Puerariae and Fructus Crataegi mixture inhibits renal injury in type 2 diabetes via decreasing of AKT/PI3K
Radix puerariae (RP) is a herbal medicines for diabetes, mainly because of anti-oxidative, insulin resistance and hypoglycemic effect. Fructus crataegi (FC) also possesses strong antioxidant activity in vitro. This study focused on the effects of herbal mixture of RP and FC (RPFC) on renal protection through a diabetic rat model. Type 2 Diabetic model was established with high fat diet followed by injecting rats a low dose of STZ (25 mg/kg body weight). Rats were randomly divided into five groups: normal, high fat diet, diabetes mellitus, high fat diet plus RPFC prevention, and RPFC prevention before diabetes mellitus. RPFC was given to rats daily by intragastric gavage. The blood bio-chemical index and renal pathological changes were examined. The later includes hematoxylin and eosin staining, periodic acid schiff staining, and Masson trichrome staining. Protein levels of were determined by Western blot and immunohistochemical staining. mRNA levels were detected by RT-PCR. Rats prevented with RPFC resulted in decreasing blood glucose with corresponding vehicle treated rats. Glomerulus mesangial matrix expansion, renal capsule constriction, and renal tubular epithelial cell edema were less severe following RPFC prevention. Moreover, RPFC prevention reduced protein levels of PI3K, AKT, α-SMA and collagen IV in the kidney of diabetic rats. Combined prevention with RPFC may inhibit the PI3K/AKT pathway in the kidney, thereby prevent renal injury in diabetic rats.
- 8 September 2017
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 17 (1) , 1-9
Open AccessRadix Puerariae and Fructus Crataegi mixture inhibits renal injury in type 2 diabetes via decreasing of AKT/PI3K
Radix puerariae (RP) is a herbal medicines for diabetes, mainly because of anti-oxidative, insulin resistance and hypoglycemic effect. Fructus crataegi (FC) also possesses strong antioxidant activity in vitro. This study focused on the effects of herbal mixture of RP and FC (RPFC) on renal protection through a diabetic rat model. Type 2 Diabetic model was established with high fat diet followed by injecting rats a low dose of STZ (25 mg/kg body weight). Rats were randomly divided into five groups: normal, high fat diet, diabetes mellitus, high fat diet plus RPFC prevention, and RPFC prevention before diabetes mellitus. RPFC was given to rats daily by intragastric gavage. The blood bio-chemical index and renal pathological changes were examined. The later includes hematoxylin and eosin staining, periodic acid schiff staining, and Masson trichrome staining. Protein levels of were determined by Western blot and immunohistochemical staining. mRNA levels were detected by RT-PCR. Rats prevented with RPFC resulted in decreasing blood glucose with corresponding vehicle treated rats. Glomerulus mesangial matrix expansion, renal capsule constriction, and renal tubular epithelial cell edema were less severe following RPFC prevention. Moreover, RPFC prevention reduced protein levels of PI3K, AKT, α-SMA and collagen IV in the kidney of diabetic rats. Combined prevention with RPFC may inhibit the PI3K/AKT pathway in the kidney, thereby prevent renal injury in diabetic rats.
- 1 June 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 90, 777-785
Cortex Mori Radicis extract attenuates myocardial damages in diabetic rats by regulating ERS
- 1 June 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 90, 777-785
Cortex Mori Radicis extract attenuates myocardial damages in diabetic rats by regulating ERS
- Open Access
- 11 August 2014
- Published by Wiley in The Anatomical Record
- Vol. 297 (12) , 2273-2279
miR‐129‐1‐3p Promote BGC‐823 Cell Proliferation by Targeting PDCD2
MicroRNAs (miRNAs) are the class of small noncoding RNAs, and play an important role in the regulation of gene expression at the posttranscriptional level. In this study, we explored the effect of miR‐129‐1‐3p on the growth and cell cycle of human gastric cancer cell line BGC‐823. The miR‐129‐1‐3p mimics or inhibitors were transfected into the BGC‐823 cell line, and the cell cycle and cell growth was measured by flow cytometry and real‐time cell analyzer, respectively. The possible targets of miR‐129‐1‐3p were analyzed by quantitative real time‐PCR (QRT‐PCR), Western blotting and Luciferase reporter assay. The results showed that miR‐129‐1‐3p could promote the growth and cell cycle of BGC‐823 cells. Although protein expression of programmed cell death 2 (PDCD2) was not changed with miR‐129‐1‐3p, QRT‐PCR showed that expression of PDCD2 mRNA was negatively related to the miR‐129‐1‐3p. Luciferase reporter assay revealed that PDCD2 is one of the targets of miR‐129‐1‐3p. Our results indicated that miR‐129‐1‐3p might promote proliferation of BGC‐823 cells by targeting PDCD2. Anat Rec, 297:2273–2279, 2014.
- 11 August 2014
- Published by Wiley in The Anatomical Record
- Vol. 297 (12) , 2273-2279
Open AccessmiR‐129‐1‐3p Promote BGC‐823 Cell Proliferation by Targeting PDCD2
MicroRNAs (miRNAs) are the class of small noncoding RNAs, and play an important role in the regulation of gene expression at the posttranscriptional level. In this study, we explored the effect of miR‐129‐1‐3p on the growth and cell cycle of human gastric cancer cell line BGC‐823. The miR‐129‐1‐3p mimics or inhibitors were transfected into the BGC‐823 cell line, and the cell cycle and cell growth was measured by flow cytometry and real‐time cell analyzer, respectively. The possible targets of miR‐129‐1‐3p were analyzed by quantitative real time‐PCR (QRT‐PCR), Western blotting and Luciferase reporter assay. The results showed that miR‐129‐1‐3p could promote the growth and cell cycle of BGC‐823 cells. Although protein expression of programmed cell death 2 (PDCD2) was not changed with miR‐129‐1‐3p, QRT‐PCR showed that expression of PDCD2 mRNA was negatively related to the miR‐129‐1‐3p. Luciferase reporter assay revealed that PDCD2 is one of the targets of miR‐129‐1‐3p. Our results indicated that miR‐129‐1‐3p might promote proliferation of BGC‐823 cells by targeting PDCD2. Anat Rec, 297:2273–2279, 2014.
- 10 July 2014
- Published by Springer Nature in Medical Oncology
- Vol. 31 (8) , 1-6
miR-129-1-3p inhibits cell migration by targeting BDKRB2 in gastric cancer
MicroRNAs (miRNAs) are a class of small noncoding RNAs, which regulate gene expression in the posttranscriptional level. They are involved in cancer occurrence and development. Different members of the same miRNA family may have different roles. Since the fact that metastasis is the main cause of cancer-related death and miR-129 has three members, in this study, we focused on the migration inhibitory role of miR-129-1-3p in gastric cancer and explored the possible mechanisms. We first compared the expression of three miR-129 family members, miR-129-5p, miR-129-1-3p, and miR-129-2-3p, between gastric carcinoma tissues and surgical margin non-cancer samples by quantitative real-time reverse transcription-polymerase chain reaction (QRT-PCR). Then, we selected miR-129-1-3p for further analysis and transfected its mimic and inhibitor into gastric cancer BGC-823 cells, respectively. Then, we compared the BGC-823 cells’ migration capacity by transwell assay. Finally, we predicted the possible targets of miR-129-1-3p and selected one target for further analysis by QRT-PCR and luciferase reporter assay. The results showed that the expression of miR-129-1-3p in gastric carcinoma was significantly lower than that in surgical margin samples. And miR-129-1-3p could inhibit the migration of BGC-823 cells. From the candidates, we selected bradykinin receptor B2 (BDKRB2), which was reported relating to metastasis, as a target for further analysis. QRT-PCR showed that the expression of BDKRB2 was negatively related to miR-129-1-3p. Luciferase reporter assay showed that BDKRB2 was the target of the miR-129-1-3p. In summary, miR-129-1-3p inhibits the BGC-823 cell migration by targeting BDKRB2.
- 10 July 2014
- Published by Springer Nature in Medical Oncology
- Vol. 31 (8) , 1-6
miR-129-1-3p inhibits cell migration by targeting BDKRB2 in gastric cancer
MicroRNAs (miRNAs) are a class of small noncoding RNAs, which regulate gene expression in the posttranscriptional level. They are involved in cancer occurrence and development. Different members of the same miRNA family may have different roles. Since the fact that metastasis is the main cause of cancer-related death and miR-129 has three members, in this study, we focused on the migration inhibitory role of miR-129-1-3p in gastric cancer and explored the possible mechanisms. We first compared the expression of three miR-129 family members, miR-129-5p, miR-129-1-3p, and miR-129-2-3p, between gastric carcinoma tissues and surgical margin non-cancer samples by quantitative real-time reverse transcription-polymerase chain reaction (QRT-PCR). Then, we selected miR-129-1-3p for further analysis and transfected its mimic and inhibitor into gastric cancer BGC-823 cells, respectively. Then, we compared the BGC-823 cells’ migration capacity by transwell assay. Finally, we predicted the possible targets of miR-129-1-3p and selected one target for further analysis by QRT-PCR and luciferase reporter assay. The results showed that the expression of miR-129-1-3p in gastric carcinoma was significantly lower than that in surgical margin samples. And miR-129-1-3p could inhibit the migration of BGC-823 cells. From the candidates, we selected bradykinin receptor B2 (BDKRB2), which was reported relating to metastasis, as a target for further analysis. QRT-PCR showed that the expression of BDKRB2 was negatively related to miR-129-1-3p. Luciferase reporter assay showed that BDKRB2 was the target of the miR-129-1-3p. In summary, miR-129-1-3p inhibits the BGC-823 cell migration by targeting BDKRB2.